Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients
Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous…
Category: News
Breaking health news, medical updates, policy changes, and public health developments from around the world. We deliver timely, accurate health journalism to keep you informed and aware.
Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients
Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart…
Atorvastatin reduces major cardiovascular events but misses disability-free survival goal
Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not…
REACT study maps widespread silent atherosclerosis across adult lifespan
Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to results from the…
Immediate evolocumab use after heart attack improves cholesterol goals but not survival
Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction…
Investigational anti-interleukin-6 monoclonal antibody achieves durable inflammatory biomarker reductions
The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic…
New study detects silent atherosclerosis in healthy young adults
Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear. An international study led by Professor…
New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage
Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial fibrillation who had…
Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients
The interleukin-6 (IL-6) antibody, pacibekitug, produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the phase…
Researchers identify early molecular warning signs of inflammatory bowel disease
Researchers have uncovered early molecular warning signs of inflammatory bowel disease, revealing the condition can begin before symptoms appear and…